Short answer
Crinetics Pharmaceuticals, Inc. (CRNX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $11M (up 2873.4% year over year) with net income of −$128M.
Q1 2026 key financials · XBRL
- Revenue
- $11M
- +2873.4% YoY
- Net income
- −$128M
- −32.1% YoY
- Operating margin
- -1307.8%
- EPS (diluted)
- −$1.23
- −18.3% YoY
Source: XBRL data from the Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 10-Q on SEC EDGAR. USD.
Crinetics Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $10.734M, up $10.373M YoY, driven by PALSONIFY product revenue of $10.306M
- Net loss $127.845M vs $96.774M YoY, with operating loss $140.378M vs $111.405M
- Atumelnant R&D $20.267M, up $12.518M YoY, versus paltusotine R&D $11.869M, down $5.382M
- Cash, equivalents and investments $1.291B, up $263.417M from December 31, 2025
- Operating cash outflow $124.703M, up 41% YoY; January stock offering netted approximately $380.0M
- Capital sufficient for at least twelve months; R&D and SG&A expected to increase as pipeline and commercialization advance
Risk Factors
- No Risk Factors section provided; excerpt contains Items 2–6 and signatures only
- New insider-trading disclosure: Chief Scientific Officer adopted a Rule 10b5-1 plan for up to 126,619 shares
- Trading-plan sales scheduled from February 19, 2026 through May 15, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Crinetics Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.